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A B S T R A C T
Enteroviruses (EV) can cause severe neurological and respiratory infections, and occasionally lead to devastating
outbreaks as previously demonstrated with EV-A71 and EV-D68 in Europe. However, these infections are still
often underdiagnosed and EV typing data is not currently collected at European level. In order to improve EV
diagnostics, collate data on severe EV infections and monitor the circulation of EV types, we have established
European non-polio enterovirus network (ENPEN). First task of this cross-border network has been to ensure
prompt and adequate diagnosis of these infections in Europe, and hence we present recommendations for non-
polio EV detection and typing based on the consensus view of this multidisciplinary team including experts from
over 20 European countries. We recommend that respiratory and stool samples in addition to cerebrospinal ﬂuid
(CSF) and blood samples are submitted for EV testing from patients with suspected neurological infections. This
is vital since viruses like EV-D68 are rarely detectable in CSF or stool samples. Furthermore, reverse transcriptase
PCR (RT-PCR) targeting the 5′noncoding regions (5′NCR) should be used for diagnosis of EVs due to their
sensitivity, speciﬁcity and short turnaround time. Sequencing of the VP1 capsid protein gene is recommended for
EV typing; EV typing cannot be based on the 5′NCR sequences due to frequent recombination events and should
not rely on virus isolation. Eﬀective and standardized laboratory diagnostics and characterisation of circulating
virus strains are the ﬁrst step towards eﬀective and continuous surveillance activities, which in turn will be used
to provide better estimation on EV disease burden.
1. Introduction – why should we diagnose enterovirus infections?
Enteroviruses (EVs) and human rhinoviruses (HRVs) are members of
the Enterovirus genus of the virus family Picornaviridae. EVs infecting
humans are classiﬁed into four species (A–D) and HRVs into three
species (A–C) on the basis of genetic divergence [1]. The most well-
known are polioviruses (PV), classiﬁed within species C enteroviruses
and the target of a global polio eradication program. This guideline
focuses on the detection and characterisation of non-polio en-
teroviruses.
EVs are a common cause of self-limiting febrile illnesses in infants
and young children but can occasionally cause severe disease including
meningoencephalitis, myelitis, paralysis, myocarditis, sepsis-like syn-
drome, respiratory disease and acute hepatitis [2–4]. EVs are now re-
cognised as the most common cause of meningitis, and infections with
some EV types also been linked to acute ﬂaccid myelitis (AFM) and
paralysis (AFP) [5]. Whereas both AFM and AFP involve clinical signs
of rapid limb weakness with low muscle tone, changes in the gray
matter of the spinal cord demonstrated by magnetic resonance imaging
[MRI] are typical for AFM cases only [6–13]. Certain EV types, notably
EV-A71 and EV-D68, have also been associated with outbreaks, occa-
sionally resulting in signiﬁcant morbidity and mortality [6,9–18]. EV-
A71 has been responsible for large hand, foot and mouth disease
(HFMD) outbreaks associated with rare but severe cases of rhomboen-
cephalitis in Asia and, more recently, in Europe [9,10], whereas an EV-
D68 epidemic has been associated with severe respiratory disease,
occasionally leading to AFM in the Northern America and Europe
[6,11–18]. The potential neurotropism of EVs and their ability to cause
severe infections reinforces the need for the monitoring and char-
acterization of EV types associated with these diﬀerent clinical pre-
sentations.
Enteroviruses have been recognised since the ﬁrst image of polio-
virus (PV) was taken in 1952 by electron microscopy (EM) [19]. Since
then, we have witnessed the transition from the use of EM or suckling
mice to cell culture for propagation and detection of EV, followed by
the replacement of cell culture by molecular methods. With every step,
sensitivity has been improved, and faster turnaround times for estab-
lishing a clinical diagnosis have been gained. However, the virus cul-
ture is still used for detection of PV [20].
Proper and early detection, combined with genetic characterization
of EVs in appropriately collected specimens, is essential both at the
individual and the community levels for several reasons [21,22].
Prompt laboratory diagnosis of an EV infection may reduce antibiotic
usage, limit unnecessary and costly investigations, shorten the length
of hospitalisation and minimise the risk of complications [23,24]. In
addition, it enables health care providers to respond in a timely
fashion with infection control measures as well as to evaluate the
usefulness of potential therapies such as novel antiviral or im-
munotherapies and provide clues for the further vaccine development.
Objectives for identiﬁcation of the EV types involved, especially in
patients with severe clinical presentations and for investigating
outbreaks, include:
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1) To identify EV types associated with more severe conditions and
monitor their associated disease burden;
2) To identify the speciﬁc EV type associated with outbreak;
3) To conﬁrm the absence of circulation and importation of poliovirus;
4) To monitor the molecular epidemiology and geographical distribu-
tion of EV types or strains known to be associated with severe or
speciﬁc disease, such as EV-A71 and EV-D68;
5) To detect and monitor the appearance of new EV types or new re-
combinant forms of known EV types.
Continuous surveillance will provide knowledge of EV infection
outcomes and recognition of their disease presentations, allow mon-
itoring the emergence of new EV strains, better estimation of EV disease
burden and is also required for potential implementation of vaccination
programmes (e.g. EV-A71 in China [25]). Although over 7000 EV-po-
sitive samples were successfully typed by 24 EU/EEA countries in 2015,
the extent of EV surveillance is variable across the region and the typing
data is not currently collected at European level [26].
To achieve the objectives listed above, we have established the
European Non-Polio Enterovirus Network (ENPEN) under the auspices
of the European Society for Clinical Virology (ESCV) with founder
participants from 22 European countries representing public health
institutions, clinical specialities (paediatrics, neurology, internal med-
icine, microbiology and virology), national reference laboratories as
well as academia. The ENPEN network aims to raise awareness across
professional backgrounds as a prerequisite for more eﬀective detection,
and guide surveillance activities. In addition, a cross-border non-polio
EV surveillance network is useful for harmonising diagnostic methods,
obtaining and sharing epidemiological data as well as for the detection
of outbreaks and emerging EVs. Such a network enables not only the
exchange of knowledge and experience but also real-time alerts at the
European level, as has been shown recently in the context of the global
emergence of EV-D68 [12]. The development of these guidelines is the
ﬁrst task undertaken by the ENPEN.
2. Aim and scope
We summarized standardized recommendations for the detection
and characterization of EVs based on a consensus view of the experts in
the ﬁeld.
3. Recommendations
3.1. What clinical specimens should be obtained for testing if EV infection is
suspected and why?
1 Sampling should be performed according to the clinical manifesta-
tions, and as soon as possible after the symptom onset (Table 1).
2 In cases of neurological infections, respiratory specimen and stool in
addition to the CSF sample and blood should be submitted for EV
testing.
Diagnostic stewardship consists of agreement on a diagnostic algo-
rithm according to diﬀerent clinical presentations and standardized
collection of clinical, epidemiological and virological data. Close col-
laboration with the clinician raising a suspicion of EV infection and
obtaining appropriate samples for diagnostic testing is vital so that
these algorithms will be followed. Clinical virologists have an important
role in promoting collection of appropriate samples in cases of EV in-
fection, including a close liaison with several clinical specialities such
as neonatology, paediatrics, neurology, dermatology and cardiology.
EVs are transmitted via the faecal-oral or respiratory route and
symptoms may develop after an incubation period of 3–21 days. Sample
collection should be performed according to clinical manifestations
(Table 1) and as soon as possible after the onset of symptoms. Specimen
materials may include stool, CSF, nasopharyngeal aspirates (NPA),
nasopharyngeal swabs, vesicular ﬂuid, bronchoalveolar lavage (BAL),
blood, conjunctival swabs, biopsy specimens (including nail tissue) and
urine.
Reasons for sampling include diagnosis of acute illnesses, outbreak
investigations and surveillance, where specimens suitable for further
typing are required. In case of suspected EV infection, multiple samples
should be collected from diﬀerent sites. The type of specimen that
would be most suitable to detect EVs will vary according to the time
from the symptom onset and clinical manifestations
Since young age is associated with an increased risk of severe out-
come of EV infection [27], patient age should be taken into account
when considering the value of diagnostic sampling. In the neonate, EV
infections can present as a sepsis-like illness with or without speciﬁc
manifestations such as myocarditis, hepatitis and encephalitis [27]; EV
can be detected in plasma, stool, respiratory secretions, as well as in
CSF or tissue biopsies.
Table 1
Recommended clinical sample types for EV diagnosis in diﬀerent clinical presentations.
Presentation Sample types* Comments
Meningitis/meningoencephalitis CSF, stool AND respiratory sample,
possible blood
EV RNA detectable in CSF in the majority of meningitis cases by PCR but inconsistently in
encephalitis cases; EV excretion in throat and stool samples is prolonged but detection does not
automatically demonstrate aetiological link.
Neonatal sepsis CSF, stool, blood AND respiratory
sample
Often diﬃcult to distinguish from meningitis. Viral load can be higher in blood than in CSF, but
requires further studies. Human parechovirus testing should also be performed, either as a ﬁrst line
investigation or if EV testing is not diagnostic.
Acute ﬂaccid paralysis/myelitis Respiratory, CSF, stool AND blood
sample*
CSF sample should be tested for enteroviruses, but in many cases of EV-D68 and EV-A71 virus has
been only detectable in respiratory tract specimen and/or stool specimen. Therefore testing of
respiratory specimen are necessary for any clinical case with CNS/paralysis/myelitis involvement. In
cases of classical AFP (without myelitis), consider also possibility of polio and obtain stool sample
for the virus detection.
HFMD/other rash Vesicle ﬂuid, respiratory sample and/
or stool
Usually high viral loads in vesicle ﬂuid. CV-A6 has been associated with onychomadesis (nail
shedding) and virus has also been recovered from ﬁnger nail in HFMD cases.
Respiratory disease Respiratory sample, possibly stool Usually nasopharyngeal aspirates or swabs recommended. Consider testing for both HRV and EV,
and consider also cross-reactivity of PCR used.
Myocarditis Stool and respiratory sample, blood
and/or heart biopsy
Typing might be helpful as CV-Bs are typically associated with myocarditis. Tissue biopsy can be
used to conﬁrm diagnosis.
Conjunctivitis Eye swab Viral haemorrhagic conjunctivitis caused by enteroviruses is highly infectious.
CNS, central nervous system; CSF, cerebrospinal ﬂuid; CV, coxsackie virus; EV, enteroviruses, HFMD, hand, foot and mouth disease; PCR, polymerase chain reaction. * Primary sample
type has been marked as bold. ** Base line blood sample should to be collected before any blood products (i.e. intravenous immunoglobulin) are administered.
H. Harvala et al. Journal of Clinical Virology 101 (2018) 11–17
13
Pleocytosis with increased lymphocyte count is often, but not al-
ways, present in patients with EV meningitis but acellular CSF is also
common, especially in children under 3 months old [28]. Patients
suﬀering from aseptic meningitis, encephalitis or myelitis have de-
tectable virus in stool and respiratory secretions for a longer period
than spinal ﬂuid, where virus remains sometimes undetectable. Fur-
thermore, as viral loads are usually higher in stool, blood and re-
spiratory samples than in CSF, these samples should be collected for EV
identiﬁcation. Respiratory specimens should always be collected from
all AFM cases to exclude EV-D68 infection, as this virus has only rarely
been detected in CSF or stool samples [29,30]. Furthermore, stool
samples should be obtained from patients with suspected PV infection.
For respiratory illnesses, virus can be found in throat swabs and NPA or
BAL specimens. As EVs colonize the throat and gut for weeks to months,
detection in these sites must be interpreted cautiously. In acute he-
morrhagic conjunctivitis, a swab from conjunctiva can allow for de-
tection of EV-D70 or coxsackievirus A24 (CV-A24) and, in HFMD cases,
CV-A6, EV-A71 and CV-A16 can be identiﬁed in vesicular lesions,
throat and stool. In epidemic pleurodynia (Bornholm disease), pleural
ﬂuid and stool samples should be investigated. In immunocompromised
individuals, clinical presentation can be particularly non-speciﬁc and
severe; therefore, the threshold for investigation should be low (espe-
cially in patients on IgG-depleting therapies such as rituximab). It
should be noted that immunocompromised patients can shed EVs in
stools for years [30].
3.2. Methods used for primary diagnosis
1 Reverse transcriptase PCR (RT-PCR) assays targeting the 5′non-
coding region (NCR) should be used for diagnosis of enteroviruses
due to their sensitivity, speciﬁcity and a short turnaround time
(Table 2). However, it is vital to ensure that the method used will
detect all EV types and is frequently updated. All laboratories per-
forming EV testing should be accredited.
2 Virus isolation should not be used for routine diagnosis but can be
used for further characterization of EVs. Virus culture skills should
be maintained at the national level.
3 Serological methods such as ELISA and neutralisation tests should
not be used for diagnosis of acute EV infection routinely.
The number of virology laboratories performing EV testing in each
country varies from just one laboratory to over 100 laboratories per
country [26], and hence the standardisation of testing as well as
methods is vital. It is important that all laboratories have sensitive
broad-spectrum molecular diagnostic assays for detection of all EVs to
allow rapid detection of potential outbreaks (Table 2).
3.2.1. Molecular methods
RT-PCR has been shown to be far more sensitive than cell culture
[20,31,32] for detection of EVs in clinical samples. RT-PCR-based as-
says for the detection of EV RNA mainly target the highly conserved
5′NCR and are, therefore, suitable for all EV types [32–36]. Correct
sample preparation prior to nucleic acid extraction and detection is
important, especially for stool samples, which should be disaggregated
in buﬀer (e.g. saline) and clariﬁed by centrifugation to avoid PCR in-
hibition. To identify the presence of inhibitory compounds in the ex-
tracted RNA, it is important to include an internal control. Any EV
detection in stool sample should be carefully evaluated as it does not
automatically imply causation, and might simply reﬂect prolonged
extretion.
Despite their increased sensitivity and speed, some molecular de-
tection methods may fail to detect certain EV types such as EV-D68, EV-
C105 and EV-C109 [37–39]. It is important that primer and probe se-
quences are regularly reviewed to reﬂect the evolutionary and genomic
changes of the viruses, and any assay used should be validated for the
detection of a variety of diﬀerent EV types (including at least one virus
from each EV species). Several commercial real-time RT-PCR kits are
now also available for the detection of EVs. More data is needed to
conﬁrm the sensitivity of commercial assays for the detection of EV
types with divergent 5′NCR sequences [37–39]. Another complication
of some 5′NCR-based RT-PCR assays is that their detection range may
extend to human rhinoviruses, which potentially limits their usefulness
for respiratory sample screening for EVs. For practical reasons, la-
boratories should use HRV and/or EV-speciﬁc assays already at the
screening stage as typing all EV/HRV positive samples in order to
identify EV-D68 is labour intensive.
During large EV outbreaks, such as those caused by EV-A71 in Asia,
and EV-D68 in Europe and USA, type-speciﬁc RT-PCR assays have been
developed to identify and type these EVs [12,40]. Such type-speciﬁc
assays allow rapid and eﬀective identiﬁcation of the emerging virus
Table 2
Diagnostic and typing assays for non-polio enteroviruses.
Test Target Characteristics
Screening PCR 5′UTR Recommended as primary assay for EV detection. Typically detects all EV types/species with equal sensitivity (but also potentially HRVs).
Can provide semi-quantitation of viral loads.
VP4, VP1 Rapid screening for deﬁned EV types only (e.g. EV-A71, EV-D68), most likely to be used in outbreak situations or for surveillance
purposes.
Virus typing VP1 A minimum of 350nt long VP1 sequence is required for surveillance by reference laboratories. The complete VP1 sequence (∼900nt) is
necessary when assigning new EV types. Anyone describing new EV types and species should consult with the Picornavirus Study Group
(http://www.picornaviridae.com/) prior to publication to ensure use of correct nomenclature.
VP4, VP2 In case of VP1 region fails to amplify, other regions including VP2 and VP4 can be also utilized as these are generally simpler to amplify.
However, recombination within the VP4 region limits their eﬃcacy for identiﬁcation of species B EV types.
Whole genome Next Generation Sequencing (NGS) methods are being developed in order to obtain the whole genome sequence of EVs, with or without
prior ampliﬁcation of genome. It is likely going to be used for EV typing in the near future. Sequencing the whole genome (or as a
minimum the 3D polymerase gene region) is required for identiﬁcation of new recombination events and the emergence of recombinant
EVs. NGS method will also enhance the detection of mixed infections, especiallly caused by two EV types of same species.
Virus isolation Whole virus Not recommended as a front line screen. Competency in virus culture is required, useful for reference laboratories.
Virus neutralisation Isolated virus Not recommended as typing antisera are increasingly unavailable and limited in range. Requires prior virus isolation.
Serology IgM, IgG Not recommended for non-polio EVs as an IgM antibody response is not always detectable during acute disease, a second sample is
often required to demonstrate the increase in IgG levels. Furthermore, there is a high prevalence of EV antibodies in the general
population from previous exposure and, thus, serologic testing lacks clinical speciﬁcity. However, the diagnostic utility of intrathecal
antibody detection using these available assays should also be explored.
EV, enterovirus; HRV, human rhinovirus; Nt, nucleotides; VP, viral protein.
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strain during outbreaks, which is crucial for clinical and public health
responses. Type-speciﬁc assays need also to be updated and re-validated
regularly.
3.2.2. Cell culture
Although cell culture should no longer be used for routine EV di-
agnosis, we encourage reference laboratories to maintain virus culture
facilities, to collect EV strains and make them available for diagnostics
developmental work. Cell culture can be used for conﬁrmation of PCR-
negative specimens in case of a suspected new variant, for detection of
more than one viral strain in a specimen, for typing by neutralisation,
for microneutralisation assays to measure serum neutralizing anti-
bodies, for assessment of eﬀects of antivirals as well as for quality
control purposes. For specimen collection, preparation for cell culture
and methodology in virus isolation see guidelines by the WHO [41,42].
Antibody panels previously used to conﬁrm EV serotype will no longer
be provided by WHO collaboration with the National Institute for
Public Health and the Environment, the Netherlands [26], but are still
available via commercial routes.
Many EVs can be isolated in cell cultures of mammalian cell lines
[43]. Often, at least three diﬀerent cell lines, usually including monkey
kidney cells and human ﬁbroblasts are used [42]. It should be noted
that species A EVs including EV-A71 grow poorly in cell cultures [36],
and EV-D68 requires lower incubation temperatures than normally
applied for EVs [44].
3.2.3. Serology
For the laboratory-conﬁrmation of acute EV infection, serological
methods such as ELISA and neutralisation tests are obsolete. Although
speciﬁc IgM and IgG assays for EVs have been described and are
available, their clinical utility is limited due to the cross-reactivity of
the antigens used between the diﬀerent serotypes. The two week in-
terval between acute and convalescent samples makes diagnosis slow
and often clinically irrelevant. However, when myocarditis, pericarditis
or cardiomyopathy is suspected and direct sampling impossible, anti-
body detection can be useful for diagnosis.
Neutralization assays can be used to quantify neutralizing anti-
bodies against selected EV type [34]. They are useful for seroprevalence
studies to assess population immunity or for individual serological ex-
amination of paired serum samples. A 4-fold increase in EV-speciﬁc
antibody concentrations between the acute and convalescent samples is
diagnostic of recent infection, and 1:8 titre in neutralisation test would
indicate protective antibody levels. However, as neutralisation assays
are necessarily serotype-speciﬁc, testing for several EV antibodies is
time-consuming and laboratory-intensive due to inherent requirements
for diﬀerent EV types.
3.3. State-of-the-art – enterovirus typing
1 Sequencing part of the VP1 capsid protein gene is the gold standard
for EV typing, and should be performed according to the WHO re-
commendations [45].
2 5′NCR sequencing should not be used for EV type identiﬁcation
3 Use VP2 and VP4 capsid protein gene sequencing for EV typing if
VP1 sequencing fails
4 Consider sequencing additional parts of the genome or obtaining full
genome sequence if a new recombinant form of EV is suspected.
Within the EU/EEA region, EV typing is performed in most national
reference laboratories (26/29 countries) but also at local virology la-
boratories (11/29 countries) [26]. The referral of samples to reference
laboratories for virus typing or sharing typing data is essential for ef-
fective monitoring of EV circulation and the early detection of emerging
virus types at a national level. Eﬀective monitoring additionally re-
quires that both screening assays and typing methods used are of
comparable sensitivity and eﬀectiveness for detection of diﬀerent EV
types and species.
Sequence relationships in any genome region are predictive of EV
species except the 5′NCR. Originally, the assignment of EV types within
species was based on cross-neutralisation properties. Later, it was
shown that these correlate well with sequence divergence in VP1 region
[46]. The term ”type” can be used to describe both genotypic assign-
ments and those based on neutralisation properties.
Recombination is a frequent event between EV types within the
same species and usually occurs between structural and non-structural
regions in EV species A-C (but rarely if at all in EV-D or human rhi-
novirus species A–C) [47]. There are also further recombinations in all
species between the structural gene region and the 5′NCR. For these
reasons, type identiﬁcation should be based on VP1 (or potentially VP2
or VP3) sequences EV species A–C (and recommended for EV-D and
HRVs). The use of VP4 for type identiﬁcation is also acceptable for all
species except EV-B.
Sequencing all or part of the VP1 capsid protein gene is the gold
standard for EV typing [45,48]. A generic assay based on WHO re-
commendation is widely used in national laboratories [45,49]. Mole-
cular typing assays based on species-speciﬁc and type-speciﬁc primers,
or on other genomic regions (capsid proteins VP4-VP2) are also used
[50–52], some of which have increased sensitivity. However, this will
limit the comparability of the data between other centres using the VP1
typing. The complete VP1 sequence (∼900 nucleotides) is used for
formal type identiﬁcation, and is required for assignment of new types.
Sequencing multiple parts or the full-length genome is used to address
speciﬁc epidemiological and research questions, including the emer-
gence of recombinant EVs and the identiﬁcation of recombination
events [47,53–55]. Several bioinformatics typing tools are available for
EV type identiﬁcation (Table 1, Supplementary Data).
4. Future directions for enterovirus detection and
characterisation
It is crucial that, as technology advances, laboratories progress to-
wards implementation of high throughput state-of-art genome sequen-
cing assays to rapidly characterise and respond to EVs. By doing so, we
may avoid the burden of design and implementation of type-speciﬁc
RT-PCR assays. Many university hospitals are well equipped to enable
them to detect and characterise EV strains collected from diagnostic
specimens. These data should be collectively shared among the com-
munity. The roles of national laboratories, in this context, are: (1) co-
ordinated response and support in management of outbreaks by rapid
identiﬁcation and characterisation of emerging EV strains; (2) con-
tinuous support to general clinical laboratories through development,
standardisation, dissemination and support in quality control of ﬁrst
line broad-spectrum EV molecular diagnostics; and (3) maintenance of
a repository of relevant up-to-date methods for detection and char-
acterization of EVs. However, speciﬁc diagnostic skills including virus
isolation and histopathological investigations should not be forgotten as
they can provide vital tools to investigate newly emerging, less well-
characterised or rarer enteroviruses. Histopathological methods in-
cluding in situ hybridisation or immunohistochemistry can also be used
to investigate the pathogenesis and/or to conﬁrm diagnosis (e.g. me-
ningoencephalitis, myocarditis) in tissue biopsies [56–58].
With the establishment of the ENPEN and the successful colla-
borative eﬀorts documented here, the goal of a strong future network is
to provide Europe with a platform for EV surveillance and data sharing.
A network with up-to-date-guidelines and real-time sharing of in-
formation (including sequences) on emerging EVs causing outbreaks
and/or severe disease will strengthen cross-border threat detection and,
hopefully, ensure rapid control of disease spread. Control of EVs is
important in the era of future polio-eradication where other EVs than
poliovirus are likely to become an increasing important cause of severe
infections associated with potential devastating consequences.
H. Harvala et al. Journal of Clinical Virology 101 (2018) 11–17
15
Funding
No funding received.
Competing interest
None of the authors have declared a competing interest.
Ethical
Not required as no patient material analysed or presented.
Conﬂicts of interest
None.
Acknowledgements
DJA is aﬃliated to the National Institute for Health Research Health
Protection Research Unit (NIHR HPRU) in Gastrointestinal Infections at
University of Liverpool in partnership with Public Health England
(PHE), in collaboration with University of East Anglia, University of
Oxford and the Quadram Institute (grant reference code HPRU-2012-
10038). DJA is based at the London School of Hygiene and Tropical
Medicine. We would like to thank European Society for Clinical
Virology (ESCV) for their support during the establishment of European
Non-Polio Enterovirus Network (ENPEN).
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in the
online version, at https://doi.org/10.1016/j.jcv.2018.01.008.
References
[1] N.J. Knowles, T. Hovi, T. Hyypiä, A.M.Q. King, A.M. Lindberg, M.A. Pallansch,
et al., Picornaviridae, in: A.M.Q. King, M.J. Adams, E.B. Carstens, E.J. Lefkowitz
(Eds.), Virus Taxonomy: Classiﬁcation and Nomenclature of Viruses: Ninth Report
of the International Committee on Taxonomy of Viruses, Elsevier, San Diego, 2012,
pp. 855–880.
[2] D. Antona, M. Kossorotoﬀ, I. Schuﬀenecker, A. Mirand, M. Leruez-Ville, C. Bassi,
et al., Severe paediatric conditions linked with EV-A71 and EV-D68, France, May to
October 2016, Eurosurveillance 21 (46) (2016).
[3] M. Pallansch, S. Oberste, L.J. Whitton, Enteroviruses: polioviruses, coxsack-
ieviruses, echoviruses, and newer enteroviruses, in: D.M. Knipe, P.M. Howley
(Eds.), Fields' Virology, 6th ed., Lippincott Williams & Wilkins, Philadelphia, PA
19106, USA, 2013.
[4] M.J. Abzug, The enteroviruses: problems in need of treatments, J. Infect. 68 (Suppl.
1) (2014) S108–114.
[5] S. Suresh, S. Forgie, J. Robinson, Non-polio enterovirus detection with acute ﬂaccid
paralysis: a systematic review, J. Med. Virol. 90 (2017) 3–7.
[6] I. Schuﬀenecker, A. Mirand, L. Josset, C. Henquell, D. Hecquet, L. Pilorge, et al.,
Epidemiological and clinical characteristics of patients infected with enterovirus
D68, France, July to December 2014, Eurosurveillance 21 (19) (2016).
[7] S.E. Midgley, C.B. Christiansen, M.W. Poulsen, C.H. Hansen, T.K. Fischer,
Emergence of enterovirus D68 in Denmark, June 2014 to February 2015,
Eurosurveillance 20 (17) (2015).
[8] H.L. Teoh, S.S. Mohammad, P.N. Britton, T. Kandula, M.S. Lorentzos, R. Booy, et al.,
Clinical characteristics and functional motor outcomes of enterovirus 71 neurolo-
gical disease in children, JAMA Neurol. 73 (3) (2016) 300–307.
[9] https://ecdc.europa.eu/sites/portal/ﬁles/media/en/publications/Publications/07-
06-2016-RRA-Enterovirus%2071-Spain.pdf.
[10] T. Solomon, P. Lewthwaite, D. Perera, M.J. Cardosa, P. McMinn, M.H. Ooi,
Virology, epidemiology, pathogenesis, and control of enterovirus 71, Lancet Infect.
Dis. 10 (2010) 778–790.
[11] C.M. Midgley, M.A. Jackson, R. Selvarangan, G. Turabelidze, E. Obringer,
D. Johnson, et al., Severe respiratory illness associated with enterovirus
D68–Missouri and Illinois, 2014, MMWR Morb. Mortal. Wkly. Rep. 63 (36) (2014)
798–799.
[12] R. Poelman, I. Schuﬀenecker, C. Van Leer-Buter, L. Josset, H.G. Niesters, B. Lina,
European surveillance for enterovirus D68 during the emerging North-American
outbreak in 2014, J. Clin. Virol. 71 (2015) 1–9.
[13] K. Messacar, T.L. Schreiner, J.A. Maloney, A. Wallace, J. Ludke, M.S. Oberste, et al.,
A cluster of acute ﬂaccid paralysis and cranial nerve dysfunction temporally asso-
ciated with an outbreak of enterovirus D68 in children in Colorado, USA, Lancet
385 (9978) (2015) 1662–1671.
[14] M. Knoester, E.H. Scholvinck, R. Poelman, S. Smit, C.L. Vermont, H.G. Niesters,
et al., Upsurge of enterovirus D68, the Netherlands, 2016, Emerg. Infect. Dis. 23 (1)
(2017) 140–143.
[15] R. Dyrdak, M. Grabbe, B. Hammas, J. Ekwall, K.E. Hansson, J. Luthander, et al.,
Outbreak of enterovirus D68 of the new B3 lineage in Stockholm, Sweden, August
to September 2016, Eurosurveillance 21 (46) (2016).
[16] D. Casas-Alba, M.F. de Sevilla, A. Valero-Rello, C. Fortuny, J.J. García-García,
C. Ortez, et al., Outbreak of brainstem encephalitis associated with enterovirus-A71
in Catalonia, Spain (2016): a clinical observational study in a children's reference
centre in Catalonia, Clin. Microbiol. Infect. 23 (11) (2017).
[17] M. Lang, A. Mirand, N. Savy, C. Henquell, S. Maridet, R. Perignon, et al., Acute
ﬂaccid paralysis following enterovirus D68 associated pneumonia, France,
Eurosurveillance 19 (44) (2014).
[18] C.J. Williams, R.H. Thomas, T.P. Pickersgill, M. Lyons, G. Lowe, R.E. Stiﬀ, et al.,
Cluster of atypical adult Guillain-Barre syndrome temporally associated with neu-
rological illness due to EV-D68 in children, South Wales, United Kingdom, October
2015 to January 2016, Eurosurveillance 21 (4) (2016).
[19] C.S. Goldsmith, S.E. Miller, Modern uses of electron microscopy for detection of
viruses, Clin. Microbiol. Rev. 22 (4) (2009) 552–563.
[20] T. Chonmaitree, C. Ford, C. Sanders, H.L. Lucia, Comparison of cell cultures for
rapid isolation of enteroviruses, J. Clin. Microbiol. 26 (12) (1988) 2576–2580.
[21] C.C. Van Leer, R. Poelman, R. Borger, H.G.M. Niesters, Newly identiﬁed enterovirus
C Genotypes, Identiﬁed in the Netherlands through routine sequencing of all en-
teroviruses detected in clinical materials from 2008 to 2015, J. Clin. Microbiol. 54
(9) (2016) 2306–2314.
[22] H. Harvala, J. Calvert, D. Van Nguyen, L. Clasper, N. Gadsby, P. Molyneaux, et al.,
Comparison of diagnostic clinical samples and environmental sampling for en-
terovirus and parechovirus surveillance in Scotland, 2010 to 2012, Eurosurveillance
19 (15) (2014).
[23] C. Ramers, G. Billman, M. Hartin, S. Ho, M.H. Sawyer, Impact of a diagnostic cer-
ebrospinal ﬂuid enteroviurs polymerase chain reaction test on patient management,
JAMA 21 (20) (2000) 2680–2685 283.
[24] C.C. Robinson, M. Willis, A. Meagher, K.E. Gieseker, H. Rotbart, M.P. Glode, Impact
of rapid polymerase chain reaction results on management of pediatric patients
with enteroviral meningitis, Pediatr. Infect. Dis. J. 21 (4) (2002) 283–286.
[25] F. Zhu, W. Xu, J. Xia, Z. Liang, Y. Liu, X. Zhang, et al., Eﬃcacy, safety, and im-
munogenicity of an enterovirus 71 vaccine in China, N. Engl. J. Med. 370 (9) (2014)
818–828.
[26] H. Harvala, A. Jasir, P. Penttinen, L. Pastore, D. Greco, E. Broberg, Surveillance and
laboratory detection for non-polio enteroviruses in the EU/EEA region,
Eurosurveillance 22 (45) (2017), http://dx.doi.org/10.2807/1560-7917.
[27] N. Khetsuriani, A. Lamonte, M.S. Oberste, M. Pallansch, Neonatal enterovirus in-
fections reported to the national enterovirus surveillance system in the United
States, 1983–2003, Pediatr. Infect. Dis. J. 25 (10) (2006) 889–893.
[28] M.A. Verboon-Maciolek, T.G. Krediet, L.J. Gerards, L.S. de Vries, F. Groenendaal,
A.M. van Loon, Severe neonatal parechovirus infection and similarity with en-
terovirus infection, Pediatr. Infect. Dis. J. 27 (3) (2008) 241–245.
[29] A. Meijer, S. van der Sanden, B.E. Snijders, G. Jaramillo-Gutierrez, L. Bont, C.K. van
der Ent, et al., Emergence and epidemic occurrence of enterovirus 68 respiratory
infections in The Netherlands in 2010, Virology 423 (1) (2012) 49–57.
[30] J. Mahony, Detection of respiratory viruses by molecular methods, Clin. Microbiol.
Rev. 12 (2008) 716–747.
[31] M. Beld, R. Minnaar, J. Weel, C. Sol, M. Damen, H. van der Avoort, et al., Highly
sensitive assay for detection of enterovirus in clinical specimens by reverse tran-
scription-PCR with an armored RNA internal control, J. Clin. Microbiol. 42 (7)
(2004) 3059–3064.
[32] M. Iturriza-Gómara, B. Megson, J. Gray, Molecular detection and characterization
of human enteroviruses directly from clinical samples using RT-PCR and DNA se-
quencing, J. Med. Virol. 78 (2) (2006) 243–253.
[33] G.J. van Doornum, M. Schutten, J. Voermans, G.J. Guldemeester, H.G. Niesters,
Development and implementation of real-time nucleic acid ampliﬁcation for the
detection of enterovirus infections in comparison to rapid culture of various clinical
specimens, J. Med. Virol. 79 (12) (2007) 1868–1876.
[34] M. Nijhuis, N. van Maarseveen, R. Schuurman, S. Verkuijlen, M. de Vos,
K. Hendriksen, et al., Rapid and sensitive routine detection of all member of the
genus enteroviurs in diﬀerent clinicla specimens by real-time PCR, J. Clin.
Microbiol. 40 (10) (2002) 3666–3670.
[35] V.A. Janes, R. Minnaar, G. Koen, Eijk H. Van, K.D. Haan, D. Pajkrt, et al., Presence
of human non-polio enterovirus and parechovirus genotypes in an Amsterdam
hospitalin 2007 to 2011 compared to national and international published sur-
veillance data: a comprehensive review, EuroSurveillance 19 (46) (2014) 1–9.
[36] G. Jaramillo-Gutierrez, K.S. Benschop, E.C. Claas, A.S. de Jong, A.M. van Loon,
S.D. Pas, et al., September through October 2010 multi-centre study in the
Netherlands examining laboratory ability to detect enterovirus 68, an emerging
respiratory pathogen, J. Virol. Methods 190 (1–2) (2013) 53–62.
[37] A. Piralla, C. Daleno, A. Scala, D. Greenberg, V. Usonis, N. Principi, et al., Genome
characterisation of enteroviruses 117 and 118: a new group within human en-
terovirus species C, PLoS One 8 (4) (2013) e60641.
[38] G. Jaramillo-Gutierrez, K.S. Benschop, E.C. Claas, A.S. de Jong, A.M. van Loon,
S.D. Pas, et al., September through October 2010 multi-centre study in the
Netherlands examining laboratory ability to detect enterovirus 68, an emerging
respiratory pathogen, J. Virol. Methods 190 (1–2) (2013) 53–62.
[39] G. Dunn, D. Klapsa, T. Wilton, L. Stone, P.D. Minor, J. Martin, Twenty-eight years of
poliovirus replication in an immunodeﬁcient individual: impact on the global polio
eradication initiative, PLoS Pathog. 11 (8) (2015) e1005114.
H. Harvala et al. Journal of Clinical Virology 101 (2018) 11–17
16
[40] https://www.escmid.org/escmidpublications/escmid_elibrary/material/?mid=
23086.
[41] Q. Chen, Z. Hu, Q. Zhang, M. Yu, Development and evaluation of a real-time
method of simultaneous ampliﬁcation and testing of enterovirus 71 incorporating a
RNA internal control system, J. Virol. Methods 196 (2014) 139–144.
[42] WHO, Polio Laboratory Manual, World Health Organization, Geneva, Switzerland,
2004.
[43] N.J. Schmidt, H.H. Ho, E.H. Lennette, Propagation and isolation of group A cox-
sackieviruses in RD cells, J. Clin. Microbiol. 2 (3) (1975) 183–185.
[44] S.S. Zaidi, H. Asghar, S. Sharif, M.M. Alam, Poliovirus laboratory based surveil-
lance: an overview, Methods Mol. Biol. 1387 (2016) 11–18.
[45] WHO, Enterovirus Surveillance Guidelines – Guidelines for Enterovirus Surveillance
in Support of the Polio Eradication Initiative, World Health Organization Regional
Oﬃce for Europe, 2015.
[46] P. Simmonds, J. Welch, Frequency and dynamics of recombination within diﬀerent
species of human enteroviruses, J. Virol. 80 (1) (2006) 483–493.
[47] E.C. McWilliam Leitch, M. Cabrerizo, J. Cardosa, H. Harvala, O.E. Ivanova, S. Koike,
et al., The association of recombination events in the founding and emergence of
subgenogroup evolutionary lineages of human enterovirus 71, J. Virol. 86 (5)
(2012) 2676–2685.
[48] M.S. Oberste, K. Maher, D.R. Kilpatrick, M.A. Pallansch, Molecular evolution of the
human enteroviruses: correlation of serotype with VP1 sequence and application to
picornavirus classiﬁcation, J. Virol. 73 (3) (1999) 1941–1948.
[49] W.A. Nix, M.S. Oberste, M.A. Pallansch, Sensitive, seminested PCR ampliﬁcation of
VP1 sequences for direct identiﬁcation of all enterovirus serotypes from original
clinical specimens, J. Clin. Microbiol. 44 (8) (2006) 2698–2704.
[50] D. Nasri, L. Bouslama, S. Omar, H. Saoudin, T. Bourlet, M. Aouni, et al., Typing of
human enterovirus by partial sequencing of VP2, J. Clin. Microbiol. 45 (8) (2007)
2370–2379.
[51] K.S. Benschop, J.C. Rahamat-Langendoen, H.G. van der Avoort, E.C. Claas, S.D. Pas,
R. Schuurman, et al., VIRO-TypeNed. VIRO-TypeNed, systematic molecular sur-
veillance of enteroviruses in the Netherlands between 2010 and 2014, Euro
Surveill. 21 (39) (2016).
[52] A. Mirand, F.V. le Sage, B. Pereira, R. Cohen, C. Levy, C. Archimbaud, et al.,
Ambulatory pediatric surveillance of hand, foot and mouth disease as signal of an
outbreak of coxsackievirus A6 infections, France, 2014–2015, Emerg. Infect. Dis. 22
(11) (2016) 1884–1893.
[53] R. Poelman, E.H. Schölvinck, R. Borger, H.G. Niesters, C. van Leer-Buter, The
emergence of enterovirus D68 in a Dutch University Medical Center and the ne-
cessity for routinely screening for respiratory viruses, J. Clin. Virol. 62 (2015) 1–5.
[54] J.L. Bailly, A. Mirand, C. Henquell, C. Archimbaud, M. Chambon, C. Regagnon,
et al., Repeated genomic transfers from echovirus 30 to echovirus 6 lineages in-
dicate co-divergence between co-circulating populations of the two human en-
terovirus serotypes, Infect. Genet. Evol. 11 (2) (2011) 276–289.
[55] E. Gaunt, H. Harvala, R. Österback, V.B. Sreenu, E. Thomson, M. Waris, et al.,
Genetic characterization of human coxsackievirus A6 variants associated with
atypical hand, foot and mouth disease: a potential role of recombination in emer-
gence and pathogenicity, J. Gen. Virol. 96 (5) (2015) 1067–1079.
[56] M.S. Oberste, K. Maher, D.R. Kilpatrick, M.A. Pallansch, Molecular evolution of the
human enteroviruses: correlation of serotype with VP1 sequence and application to
picornavirus classiﬁcation, J. Virol. 73 (3) (1999) 1941–1948.
[57] M. Oikarinen, S. Tauriainen, P. Penttilä, J. Keim, I. Rantala, T. Honkanen, et al.,
Evaluation of immunohistochemistry and in situ hybridization methods for the
detection of enteroviruses using infected cell culture samples, J. Clin. Virol. 47 (3)
(2010) 224–228.
[58] Z. Wang, J.M. Nicholls, F. Liu, J. Wang, Z. Feng, D. Liu, et al., Pulmonary and
central nervous system pathology in fatal cases of hand foot and mouth disease
caused by enterovirus A71 infection, Pathology (Phila.) 48 (3) (2016) 267–274.
H. Harvala et al. Journal of Clinical Virology 101 (2018) 11–17
17
